Arnaud Foussat

Company: Carmil Therapeutics

Job title: Chief Executive Officer

Seminars:

Engineering Co-Stimulation-Independent T-Cells to Overcome Tumor Immunosuppression 11:00 am

Introducing a gain-of-function gene that enhances T-Cell sensitivity to low antigen levels and bypasses CD28 costimulation Demonstrating resistance to PD-1 and CTLA-4 mediated suppression, improving efficacy in low-immunogenic tumors Exploring translational potential for TIL therapies beyond melanoma through strategic partnershipsRead more

day: Conference Day One R&D Track AM